GeneFerm Biotechnology Co Ltd (1796) — Capital Reinvestment Ratio
Latest as of June 2025:
4.13x
GeneFerm Biotechnology Co Ltd (1796) has a Capital Reinvestment Ratio of 4.13x as of June 2025, meaning it reinvests 4% of its operating cash flow (NT$1.45 Million) in capital expenditures (NT$5.98 Million). See cash generation quality of GeneFerm Biotechnology Co Ltd to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
4.13x
Capex / Operating Cash Flow
Operating Cash Flow
NT$1.45 Million
TWD
Capital Expenditures
NT$5.98 Million
TWD
Data as of
Jun 2025
Most recent filing
GeneFerm Biotechnology Co Ltd Capital Reinvestment Ratio (2017–2024)
This chart tracks GeneFerm Biotechnology Co Ltd's Capital Reinvestment Ratio across 8 annual periods.
Annual Capital Reinvestment Ratio for GeneFerm Biotechnology Co Ltd (2017–2024)
Year-by-year Capital Reinvestment Ratio for GeneFerm Biotechnology Co Ltd from 2017 to 2024. For live market cap and broader valuation context, see 1796 stock market capitalisation.
| Year | Reinvestment Ratio | Operating CF (TWD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2024 | 2.81x | NT$8.09 Million | NT$22.70 Million | ▲ +647.8% |
| 2023 | 0.38x | NT$190.31 Million | NT$71.40 Million | ▼ -83.5% |
| 2022 | 2.27x | NT$122.43 Million | NT$278.42 Million | ▲ +75.3% |
| 2021 | 1.30x | NT$112.23 Million | NT$145.61 Million | ▼ -11.1% |
| 2020 | 1.46x | NT$56.42 Million | NT$82.32 Million | ▼ -60.7% |
| 2019 | 3.72x | NT$14.69 Million | NT$54.57 Million | ▲ +443.5% |
| 2018 | 0.68x | NT$42.14 Million | NT$28.81 Million | ▼ -24.3% |
| 2017 | 0.90x | NT$61.08 Million | NT$55.16 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow